CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY

被引：0

作者：

Zhang, Mingming ^{[1
,2
]}

Hu, Yongxian ^{[1
,2
]}

Lu, Peihua ^{[3
,4
]}

Huang, Liang ^{[5
]}

Fu, Shan ^{[1
,2
]}

Feng, Jingjing ^{[1
,2
]}

Hong, Ruimin ^{[1
,2
]}

Chang, Alex H. ^{[6
]}

Huang, He ^{[1
,2
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[2] Liangzhu Lab, Hangzhou, Peoples R China

[3] Hebei Yanda Lu Daopei Hosp, Langfang, Peoples R China

[4] Lu Daopei Inst Hematol, Beijing, Peoples R China

[5] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China

[6] Shanghai YaKe Biotechnol, Shanghai, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

P007

引用

页码：146 / 146

页数：1